Nomura Initiates Inotek Pharmaceuticals At Buy

Nomura initiated coverage on

with a Buy rating. The target price for Inotek Pharmaceuticals is set to $13. Inotek Pharmaceuticals' shares jumped 7.21% to $6.10 in pre-market trading.